Combined value of left ventricular ejection fraction and the Model for End-Stage Liver Disease (MELD) score for predicting mortality in patients with acute coronary syndrome who were undergoing percutaneous coronary intervention

Table 2 Laboratory results of the study groups

Variable	Survivors (n = 663)	Non-survivors (n = 183)	P value
Peak-troponin-Ia, ng/mL	28 (19–44)	30 (18–51)	0.444^a
Peak-troponin-I^*, ng/mL	1.8 (0.6–4.2)	2.3 (0.5–12.4)	0.853^b
Total cholesterol	170 ± 40	179 ± 46	0.128
SCr^* _adm (mg/dl)	0.82 (0.73–1.02)	1.03 (0.79–1.42)	< 0.001
WBC (× 10³/mm³)	11 ± 3	12 ± 4	< 0.001
Hemoglobin (g/dl)	12.6 ± 2	11.8 ± 2.2	< 0.001
LVEF (%)	47.5 ± 10.0	41.3 ± 11.8	< 0.001
ALT^* (U/L)	32 (21–49)	28 (18–54)	0.420
AST^* (U/L)	51 (27–105)	44 (23–129)	0.321
Total bilirubin^* (mg/dl)	0.57 (0.40 ± 0.78)	0.60 (0.40–0.90)	0.015
INR	1 ± 0.11	1 ± 0.16	< 0.001
MELD score	7.8 ± 2.4	10.1 ± 4.4	< 0.001

SCr serum creatinine at admission, WBC wight blood cell, LVEF left ventricular ejection fraction, ALT alanine transaminase, AST aspartat transaminase, INR international normalised ratio, MELD model for liver end-stage liver disease
^*Comparison was made using Mann-Whitney U test at P < 0.05, and these values were described by median with inter-quartile range (25th and 75th percentile)
^aComparison was made in patients with ST-elevation myocardial infarction
^bComparison was made in patients with non-ST-elevation myocardial infarction

ISSN: 1471-2261